<DOC>
	<DOCNO>NCT02460094</DOCNO>
	<brief_summary>The purpose study evaluate safety tolerability multiple ascend intravenous infusion BMS-986168 ass pharmacodynamics BMS-986168 cerebrospinal fluid ( CSF ) extracellular tau ( eTau ) concentration patient Progressive Supranuclear Palsy .</brief_summary>
	<brief_title>Multiple Ascending Dose Study Intravenously Administered BMS-986168 Patients With Progressive Supranuclear Palsy</brief_title>
	<detailed_description />
	<mesh_term>Paralysis</mesh_term>
	<mesh_term>Supranuclear Palsy , Progressive</mesh_term>
	<criteria>Inclusion Criteria 1 . Probable possible PSP define : least 12month history postural instability fall first 3 year symptoms present decrease downward saccade velocity screening define observable eye movement deviation `` main sequence '' linear relationship saccade amplitude saccade velocity ; supranuclear ophthalmoplegia define 50 % reduction upward gaze 30 % reduction downward gaze ; age symptom onset 40 85 year history current age 41 86 year , inclusive , time screening ; akineticrigid syndrome prominent axial rigidity . presence symptom less 5 year . 2 . Body weight range ≥ 43 kg/95 lb ≤ 118 kg/260 lb . 3 . Able tolerate MRI . 4 . Able perform protocolspecified assessment comply study visit schedule . 5 . Have reliable caregiver accompany patient study visit . Caregiver must able read , understand , speak local language fluently ensure comprehension inform consent informantbased assessment patient . Caregiver must also frequent contact patient ( least 3 hour per week one time different time ) willing monitor patient 's health concomitant medication throughout study . 6 . Score ≥ 20 Mini Mental State Exam ( MMSE ) screening . 7 . Patient must reside outside skilled nursing facility dementia care facility time screening , admission facility plan . Residence assist live facility allow . 8 . Ability ambulate independently assistance defined ability take least 5 step walker ( guard allow provide contact ) ability take least 5 step without walker cane assistance another person contact one upper extremity . 9 . Stable chronic medication least 30 day prior screen . 10 . Women child bear potential ( WOCBP ) sexually active fertile men partner WOCBP must use highly effective birth control . Exclusion Criteria 1 . Presence significant neurological psychiatric disorder . 2 . History screen brain MRI scan indicative significant abnormality . 3 . History cancer within 5 year screen exception fully excise nonmelanoma skin cancer nonmetastatic prostate cancer stable least 6 month . 4 . History clinically significant hematological , endocrine , cardiovascular , renal , hepatic , gastrointestinal , neurological disease . 5 . Inability venipunctured and/or tolerate venous access . 6 . Contraindication undergo LP . 7 . Recent drug alcohol abuse define DSM IV . 8 . Treatment investigational drug ( include placebo ) device within 90 day prior screen . 9 . Contraindication MRI examination reason 10 . History clinically significant medical condition would interfere patient 's ability comply study instruction , would place patient increase risk , might confound interpretation study result . 11 . History allergy , hypersensitivity , serious adverse reaction monoclonal antibody relate compound allergy component study drug</criteria>
	<gender>All</gender>
	<minimum_age>41 Years</minimum_age>
	<maximum_age>86 Years</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>